Psychosis among substance users

Current Opinion in Psychiatry

Volumn 19, Issue 3, 2006, Pages 239-245

  Thirthalli, Jagadisha ^a   Benegal, Vivek ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Psychosis; Risk; Substance abuse

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; ALCOHOL; AMPHETAMINE; BENZODIAZEPINE; CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; KETAMINE; METHAMPHETAMINE; OPIATE; PHENCYCLIDINE;

CLINICAL TRIAL; DISEASE COURSE; FAMILIAL DISEASE; HEREDITY; HIGH RISK POPULATION; HUMAN; META ANALYSIS; NEUROBIOLOGY; PERSONALITY; PSYCHOSIS; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SUBSTANCE ABUSE; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; HUMANS; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 33745461663     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yco.0000218593.08313.fd     Document Type: Review

References (72)

1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264:2511-2518.
2. Cantor-Graae E, Nordstrom LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 2001; 48:69-82.
3. Tiihonen J, Isohanni M, Rasanen P, et al. Specific major mental disorders and criminality: a 26-year prospective study of the 1966 northern Finland birth cohort. Am J Psychiatry 1997; 154:840-845.
4. Arseneault L, Moffitt TE, Caspi A, et al. Mental disorders and violence in a total birth cohort: results from the Dunedin Study. Arch Gen Psychiatry 2000; 57:979-986.
5. van Os J, Hanssen M, Bijl RV, Ravelli A. Strauss (1969) revisited: a psychosis continuum in the general population? Schizophr Res 2000; 45:11-20.
6. World Health Organisation. Global status report on alcohol 2004. Geneva World Health Organization; 2004. pp. 1-2.
7. Johns LC, Cannon M, Singleton N, et al. Prevalence and correlates of self-reported psychotic symptoms in the British population. Br J Psychiatry 2004; 185:298-305.
8. Olfson M, Lewis-Fernandez R, Weissman MM, et al. Psychotic symptoms in an urban general medicine practice. Am J Psychiatry 2002; 159:1412-1419.
9. Glass IB. Alcoholic hallucinosis: a psychiatric enigma - 1. The development of an idea. Br J Addict 1989; 84:29-41.
10. Tsuang JW, Irwin MR, Smith TL, Schuckit MA. Characteristics of men with alcoholic hallucinosis. Addiction 1994; 89:73-78.
11. Soyka M, Dresel S, Horak M, et al. PET and SPECT findings in alcohol hallucinosis: case report and super-brief review of the pathophysiology of this syndrome. World J Biol Psychiatry 2000; 1:215-218.
12. Soyka M, Zetzsche T, Dresel S, Tatsch K. FDG-PET and IBZM-SPECT suggest reduced thalamic activity but no dopaminergic dysfunction in chronic alcohol hallucinosis. J Neuropsychiatry Clin Neurosci 2000; 12:287-288.
13. Soyka M, Koch W, Tatsch K. Thalamic hypofunction in alcohol hallucinosis: FDG PET findings. Psychiatry Res 2005; 139:259-262.
14. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry 1990; 47:1023-1028.
15. George DT, Rawlings RR, Williams WA, et al. A select group of perpetrators of domestic violence: evidence of decreased metabolism in the right hypothalamus and reduced relationships between cortical/subcortical brain structures in position emission tomography. Psychiatry Res 2004; 130:11-25.
16. Kathmann N, Soyka M, Bickel R, Engel RR. ERP changes in alcoholics with and without alcohol psychosis. Biol Psychiatry 1996; 39:873-881.
17. Connel PH. Amphetamine psychosis Maudsley monograph no. 5. London: Chapman & Hall; 1958.
18. Srisurapanont M, Ali R, Marsden J, et al. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol 2003; 6:347-352.
19. Chen CK, Lin SK, Sham PC, et al. Pre-morbid characteristics and comorbidity of methamphetamine users with and without psychosis. Psychol Med 2003; 33:1407-1414.
20. Chen CK, Lin SK, Sham PC, et al. Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet 2005; 136:87-91. This report provides a strong support to the long-held theory that those who develop psychosis with substance abuse have familial, possibly genetic, vulnerability to develop psychosis. Along with a previous report on the same sample [19], this report identifies risk factors for the development of psychosis among MAP users.
21. Giros B, Jaber M, Jones SR, et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379:606-612.
22. Iyo M, Nishio M, Itoh T, et al. Dopamine D2 and serotonin S2 receptors in susceptibility to methamphetamine psychosis detected by positron emission tomography. Psychiatry Res 1993; 50:217-231.
23. Sekine Y, Iyo M, Ouchi Y, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 2001; 158:1206-1214.
24. Sekine Y, Minabe Y, Ouchi Y, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 2003; 160:1699-1701.
25. Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158:377-382.
26. Volkow ND, Chang L, Wang GJ, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 2001; 158:2015-2021.
27. Arseneault L, Cannon M, Poulton R, et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325:1212-1213.
28. Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 2005; 100:354-366. This report is the latest to replicate the association of cannabis with psychosis with evidence for temporal precedence of cannabis and adjustment for confounding factors. Further, it uses structural equation modelling to show that cannabis has an effect on psychosis, and not the other way round.
29. van Os J, Bak M, Hanssen M, et al. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156:319-327.
30. Ferdinand RF, Sondeijker F, van der Ende J, et al. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005; 100:612-618. This prospective study, by showing that cannabis use predicts future psychotic symptoms and vice versa, lends support to the hypothesis that cannabis use and psychosis have common vulnerabilities or have bidirectional association.
31. Talbott JA, Teague JW. Marihuana psychosis. Acute toxic psychosis associated with the use of Cannabis derivatives. JAMA 1969; 210:299-302.
32. Chopra GS, Smith JW. Psychotic reactions following cannabis use in East Indians. Arch Gen Psychiatry 1974; 30:24-27.
33. Chaudry HR, Moss HB, Bashir A, Suliman T. Cannabis psychosis following bhang ingestion. Br J Addict 1991; 86:1075-1081.
34. Tennant FS Jr, Groesbeck CJ. Psychiatric effects of hashish. Arch Gen Psychiatry 1972; 27:133-136.
35. Mathers DC, Ghodse AH. Cannabis and psychotic illness. Br J Psychiatry 1992; 161:648-653.
36. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. Lancet 1988; 1:1000-1001.
37. Zammit S, Allebeck P, Andreasson S, et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002; 325:1199.
38. Weiser M, Knobler HY, Noy S, Kaplan Z. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet 2002; 14:949-955.
39. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184:110-117. This review of studies with well defined samples, where the association of cannabis with adult psychosis is examined, argues that cannabis is a component cause for psychosis.
40. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005; 19:187-194. This report has both systematic review and meta-analysis of the relationship between cannabis and psychosis. The authors did not find publication bias or heterogeneity in the studies they reviewed.
41. Verdoux H, Gindre C, Sorbara F, et al. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med 2003; 33:23-32.
42. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescentonset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene x environment interaction. Biol Psychiatry 2005; 57:1117-1127. This study gives an interesting evidence of gene x environment interaction, suggesting the role of susceptibility genes in the development of psychosis when exposed to environmental pathogens.
43. Brady KT, Lydiard RB, Malcolm R, Ballenger JC. Cocaine-induced psychosis. J Clin Psychiatry 1991; 52:509-512.
44. Bartlett E, Hallin A, Chapman B, Angrist B. Selective sensitization to the psychosis inducing effects of cocaine: a possible marker for addiction relapse vulnerability? Neuropsychopharmacology 1997; 16:77-82.
45. Satel SL, Southwick SM, Gawin FH. Clinical features of cocaine-induced paranoia. Am J Psychiatry 1991; 148:495-498.
46. Kaye S, Darke S. Injecting and non-injecting cocaine use in Sydney, Australia: physical and psychological morbidity. Drug Alcohol Rev 2004; 23:391-398. This survey of inner-city and south-western Sydney, basically aimed at examining physical and psychological harm due to cocaine, provides useful information on psychotic symptoms in cocaine users in the community.
47. Serper MR, Chou JC, Allen MH, et al. Symptomatic overlap of cocaine intoxication and acute schizophrenia at emergency presentation. Schizophr Bull 1999; 25:387-394.
48. Rosse RB, Collins JP Jr, Fay-McCarthy M, et al. Phenomenologic comparison of the idiopathic psychosis of schizophrenia and drug-induced cocaine and phencyclidine psychoses: a retrospective study. Clin Neuropharmacol 1994; 17:359-369.
49. Brady KT, Lydiard RB, Malcolm R, Ballenger JC. Cocaine-induced psychosis. J Clin Psychiatry 1991; 52:509-512.
50. Satel SL, Edell WS. Cocaine-induced paranoia and psychosis proneness. Am J Psychiatry 1991; 148:1708-1711.
51. Rosse R, Deutsch S, Chilton M. Cocaine addicts prone to cocaine-induced psychosis have lower body mass index than cocaine addicts resistant to cocaine-induced psychosis - implications for the cocaine model of psychosis proneness. Isr J Psychiatry Relat Sci 2005; 42:45-50.
52. Reid MS, Ciplet D, O'Leary S, et al. Sensitization to the psychosis-inducing effects of cocaine compared with measures of cocaine craving and cue reactivity. Am J Addict 2004; 13:305-315. This report, comparing small samples of those who showed sensitization to cocaine-induced psychosis and those who did not, shows that sensitization does not affect cue-induced craving and generates interesting discussion on the biological underpinnings of craving and psychosis.
53. Siegel RK. Cocaine smoking disorders: diagnosis and treatment. Psychiatric Ann 1984; 14:728-732.
54. Mc Lellan AT, Woody GE, O'Brien CP. Development of psychiatric illness in drug abusers. Possible role of drug preference. N Engl J Med 1979; 301:1310-1314.
55. Davies AN, Quinn T. Opioid-related musical hallucinations. J Pain Symptom Manage 2005; 29:327-328.
56. Benitez del Rosario MA, Feria M, Monton Alvarez FI. Hallucinations in an elderly cancer patient: opioid neurotoxicity or dementia with Lewy bodies? Palliat Med 2002; 16:71-72.
57. Keeley PW, Foster G, Whitelaw L. Hear my song: auditory hallucinations with tramadol hydrochloride. BMJ 2000; 321:1608.
58. Brooner RK, King VL, Kidorf M, et al. Psychiatric and substance use comorbidity among treatment-seeking opioids abusers. Arch Gen Psychiatry 1997; 54:71-80.
59. Rounsaville BJ, Weissman MM, Kleber H, Wilber C. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry 1982; 39:161-168.
60. Khantzian EJ, Treece C. DSM-III psychiatric diagnosis of narcotic addicts. Recent findings. Arch Gen Psychiatry 1985; 42:1067-1071.
61. Sorensen HJ, Jepsen PW, Haastrup S, Juel K. Drug-use pattern, comorbid psychosis and mortality in people with a history of opioid addiction. Acta Psychiatr Scand 2005; 111:244-249.
62. Landabaso MA, Iraurgi I, Jimenez-Lerma JM, et al. Ecstasy-induced psychotic disorder: six-month follow-up study. Eur Addict Res 2002; 8:133-140.
63. Bakker CB, Amini FB. Observations on the psychotomimetic effects of Sernyl. Compr Psychiatry 1961; 2:269-280.
64. Luby ED, Cohen BD, Rosenbaum F, et al. Study of a new schizophrenomimetic drug, Sernyl. Arch Neurol Psychiatry 1959; 81:363-369.
65. Farber NB. The NMDA receptor hypofunction model of psychosis. Ann N Y Acad Sci 2003; 1003:119-130.
66. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51:199-214.
67. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14:301-307.
68. Newcomer JW, Farber NB, Jevtovic-Todorovic V, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999; 20:106-118.
69. Krystal JH, Perry EB Jr, Gueorguieva R, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005; 62:985-994. This study examins two competing hypotheses of schizophrenia, namely, NMDA hypothesis and dopamine hypothesis. The results and discussion are interesting; they show that symptom dimensions of schizophrenia are likely to have distinct neurobiological substrates.
70. Byrne A, Kirby B, Zibin T, Ensminger S. Psychiatric and neurological effects of chronic solvent abuse. Can J Psychiatry 1991; 36:735-738.
71. Goldbloom D, Chouinard G. Schizophreniform psychosis associated with chronic industrial toluene exposure: case report. J Clin Psychiatry 1985; 46:350-351.
72. Cottler LB, Robins LN, Helzer JE. The reliability of the CIDI-SAM: a comprehensive substance abuse interview. Br J Addict 1989; 84:801-814.